Pharmaceutical Sector: Sequentially Flattish Quarter Expected
4QFY22 is expected to be a flattish quarter for most Pharma companies in our coverage universe. We expect a few companies to benefit from the US...
341 Views
HSIE Results Daily: DLF, Dr. Reddy’s, IndusInd Bank and More
HSIE Results Daily DLF: DLF surprised positively on presales at INR 10bn (6.6x/-5% YoY/QoQ) despite the lockdown during the quarter. While office...
96 Views
India drives earnings growth, while North America/PSAI drags it down
Dr. Reddy's Labs (DRRD) delivered a miss on earnings in 1QFY22, affected by a) higher price erosion in North America (NAM) sales, b) the deferment...
116 Views
Dr Reddys Labs: Operational Excellence and Continuous Improvement
DRRD delivered a strong performance led by the volume growth and new product launches across these markets. We expect revenue and PAT CAGR of 10.3%...
117 Views
Event Update:Dr Reddys Labs
Dr. Reddy's Laboratories Ltd (DRREDDY) offers a portfolio of products and services including APIs, custom pharmaceutical services, generics,...
209 Views